NASDAQ:MGTAMagenta Therapeutics Stock Price, Forecast & News

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MGTA stock has increased by 2.6% and is now trading at $9.40. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Magenta Therapeutics.

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Magenta Therapeutics.

Magenta Therapeutics Inc (NASDAQ:MGTA) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.09. View Magenta Therapeutics' earnings history.

3 Wall Street analysts have issued 12 month price targets for Magenta Therapeutics' stock. Their forecasts range from $18.00 to $20.00. On average, they anticipate Magenta Therapeutics' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 102.1% from the stock's current price. View analysts' price targets for Magenta Therapeutics.

Press coverage about MGTA stock has been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Magenta Therapeutics earned a news sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news aboutMagenta Therapeutics.

Magenta Therapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 1,160,000 shares, a decline of 18.9% from the April 15th total of 1,430,000 shares. Based on an average daily trading volume, of 164,100 shares, the days-to-cover ratio is currently 7.1 days. Currently, 5.6% of the shares of the company are sold short. View Magenta Therapeutics' Current Options Chain.

Some companies that are related to Magenta Therapeutics include Intra-Cellular Therapies (ITCI), Mersana Therapeutics (MRSN), Arvinas (ARVN), I-Mab (ARQT), Tricida (TCDA), Supernus Pharmaceuticals (SUPN), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Cytokinetics (CYTK), Phathom Pharmaceuticals (PHAT), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), Myovant Sciences (MYOV), Odonate Therapeutics (ODT) and Aimmune Therapeutics (AIMT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Nabriva Therapeutics (NBRV), Vaxart (VXRT), Anavex Life Sciences (AVXL), Aduro BioTech (ADRO), Cidara Therapeutics (CDTX), ImmunoGen (IMGN), Selecta Biosciences (SELB) and Sorrento Therapeutics (SRNE).

(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Magenta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Casdin Capital LLC (7.52%), Eventide Asset Management LLC (4.53%), BlackRock Inc. (4.09%), State Street Corp (0.90%), Geode Capital Management LLC (0.69%) and Ensign Peak Advisors Inc (0.20%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, David Scadden, Jason Gardner, John C Davis Jr and Michael P Cooke. View institutional ownership trends for Magenta Therapeutics.

MGTA stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Casdin Capital LLC, BlackRock Inc., Ensign Peak Advisors Inc, and State Street Corp. Company insiders that have sold Magenta Therapeutics company stock in the last year include Jason Gardner, John C Davis Jr, and Michael P Cooke. View insider buying and selling activity for Magenta Therapeutics.

MGTA stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, Two Sigma Investments LP, Nuveen Asset Management LLC, Bailard Inc., Geode Capital Management LLC, AQR Capital Management LLC, and Dynamic Technology Lab Private Ltd. Company insiders that have bought Magenta Therapeutics stock in the last two years include David Scadden, and Jason Gardner. View insider buying and selling activity for Magenta Therapeutics.

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGTA stock can currently be purchased for approximately $9.40.

Magenta Therapeutics has a market capitalization of $371.15 million. The company earns $-76,770,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.

The official website for Magenta Therapeutics is www.magentatx.com.

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]